Papataxiarchis was ARPIM vice-president in 2012.
“The main task of my mandate as ARPIM president is to strengthen the relationship between the pharmaceutical industry and the society,” Papataxiarchis said in a statement.
Papataxiarchis is a managing director of pharmaceutical companies Johnson & Johnson Romania and Janssen Romania.
ARPIM Board of Directors is made of two vice-presidents, namely Amgen Romania’s general manager Regis Lhomme, and the general manager of Astra Zeneca, Radu Rasinar, as well as of three members- Elena Mitova, general manager with Novartis, Luca Visini, general manager with Eli Lilly, Pascal Prigent, general manager with GlaxoSmithKline, and Dan Zaharescu, executive director with ARPIM.
ARPIM is made of 28 international pharmaceutical companies producing original medical drugs operating on the Romanian market, which account for over 70% of the local pharmaceutical company market.
The pharmaceutical companies members of ARPIM are Abbott Products, Alcon Pharmaceuticals Ltd., Amgen, Angelini, Astellas Pharma, AstraZeneca, Bayer – Schering A.G, Berlin Chemie-Menarini, Boehringer Ingelheim, Boiron Ro, Bristol Myers Squibb, Eli Lilly Romania SRL, GlaxoSmithKline SRL, Ipsen Pharma, Johnson & Johnson SRL, Leo Pharma A/S, Lundbeck, Merck Romania, Merck Sharp & Dohme, Mundipharma Medical GmbH, Novartis Pharma Services, Novo Nordisk Farma SRL, Pfizer Romania SRL, Sanofi Aventis, Servier Pharma SRL, Torrex – Chiesi Romania, UCB Romania, Vifor Intl.